ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

11. SEGMENTS (Tables)

11. SEGMENTS (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Summarized segment financial information

Three Months Ended March 31, 2018
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated

Revenues		$	1,666,243			$	2,340,055			$	35,708			$	4,042,006

Cost of product revenue			10,697,642				1,545,106				—				12,242,748

Loss from operations			(12,724,718	)			(1,038,824	)			(2,768,961	)			(16,532,503	)

Other expense, net			(240,054	)			(435	)			(1,049,150	)			(1,289,639	)

Net loss			(12,964,772	)			(1,039,259	)			(3,818,111	)			(17,822,142	)

Total assets			47,481,781				27,532,613				16,123,231				91,137,625

Depreciation and amortization expense			631,832				188,914				8,795				829,541

Capital expenditures			105,199				444,047				—				549,246

Three Months Ended March 31, 2017
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated

Revenues		$	—			$	2,593,163			$	35,708			$	2,628,871

Cost of product revenue			—				1,616,287				—				1,616,287

Loss from operations			—				(502,600	)			(5,434,403	)			(5,937,003	)

Other expense, net			—				—				(599,960	)			(599,960	)

Net loss			—				(502,600	)			(6,034,363	)			(6,536,963	)

Total assets			—				2,286,500				15,308,418				17,594,918

Depreciation and amortization expense			—				103,640				14,422				118,062

Capital expenditures			—				2,084				1,500				3,584